The endothelium is a dynamic component of the cardiovascular system that plays an important role in health and disease. This study tested the hypothesis that targeted delivery of endothelial cells (ECs) overexpressing neutrophil membrane IL-8 receptors IL8RA and IL8RB reduces acute myocardial infarction (MI)-induced left ventricular (LV) remodeling and dysfunction and increases neovascularization in the area at risk surrounding the infarcted tissue. MI was created by ligating the left anterior descending coronary artery in 12-wk-old male Sprague-Dawley rats. Four groups of rats were studied: group 1: sham-operated rats without MI or EC transfusion; group 2: MI rats with intravenous vehicle; group 3: MI rats with transfused ECs transduced with empty adenoviral vector (Null-EC); and group 4: MI rats with transfused ECs overexpressing IL8RA/RB (1.5 ϫ 10 6 cells post-MI). Two weeks after MI, LV function was assessed by echocardiography; infarct size was assessed by triphenyltetrazolium chloride (live tissue) and picrosirus red (collagen) staining, and capillary density and neutrophil infiltration in the area at risk were measured by CD31 and MPO immunohistochemical staining, respectively. When compared with the MI ϩ vehicle and MI-Null-EC groups, transfusion of IL8RA/RB-ECs decreased neutrophil infiltration and pro-inflammatory cytokine expression and increased capillary density in the area at risk, decreased infarct size, and reduced MI-induced LV dysfunction. These findings provide proof of principle that targeted delivery of ECs is effective in repairing injured cardiac tissue. Targeted delivery of ECs to infarcted hearts provides a potential novel strategy for the treatment of acute MI in humans. myocardial infarction; cell therapy; endothelial cells; interleukin-8 receptors; neovascularization CELL-BASED THERAPIES FOR CARDIOVASCULAR diseases have proliferated over the past decade, but with limited success (13, 30). Cell-based therapies have been shown to alleviate left ventricular (LV) remodeling and dysfunction after acute myocardial infarction (MI) in animal models and in humans (1,2,4,5,15,16,19,20,22,26,31,32). Intracoronary administration of stem cells (e.g., bone marrow-derived cells or circulating cardiac progenitor cells) can be effective in regenerating cardiac tissue and ameliorating LV remodeling and dysfunction in rodent models of acute MI, both in the setting of permanent coronary occlusion and as a result of transient occlusion followed by reperfusion (15,16,26,31,32). An important limitation of this approach is that because these cells lack a selective homing device targeting ischemic/infarcted tissues, they must be injected directly into the affected myocardium or infused into the aortic root, procedures that are invasive, costly, and difficult to adapt for widespread clinical use. Other major hurdles for successful cell therapies include 1) cell type selection (e.g., progenitor vs. differentiated), 2) cell delivery mode (e.g., peripheral vs. directly into tissue), 3) timing of cell delivery (e....